GIANT CELL ARTERITIS
Clinical trials for GIANT CELL ARTERITIS explained in plain language.
Never miss a new study
Get alerted when new GIANT CELL ARTERITIS trials appear
Sign up with your email to follow new studies for GIANT CELL ARTERITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New injection aims to tame dangerous blood vessel inflammation
Disease control CompletedThis study tested if adding a medication called secukinumab to a standard steroid taper helps people with newly diagnosed giant cell arteritis stay in remission longer. It involved 151 adults whose disease symptoms were under control. The goal was to see if the drug could delay o…
Matched conditions: GIANT CELL ARTERITIS
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 21:26 UTC
-
New scan aims to spot Blindness-Causing inflammation earlier
Diagnosis CompletedThis study tested a new type of digital PET/CT scan to see if it could accurately diagnose giant cell arteritis (GCA), a serious condition that inflames arteries and can lead to sudden blindness. Researchers compared the new scan to a standard ultrasound in 92 patients suspected …
Matched conditions: GIANT CELL ARTERITIS
Sponsor: Jewish General Hospital • Aim: Diagnosis
Last updated Mar 31, 2026 12:12 UTC
-
New scan could replace painful biopsy for common artery disease
Diagnosis CompletedThis study tested if a PET/CT scan could accurately diagnose giant cell arteritis (GCA), a common artery inflammation in people over 50. It compared the scan's accuracy to other imaging tests and the current standard, which is an invasive biopsy. The goal was to find a less painf…
Matched conditions: GIANT CELL ARTERITIS
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Diagnosis
Last updated Mar 16, 2026 15:27 UTC
-
Alcoholism drug repurposed to fight pain and fatigue in rare autoimmune diseases
Symptom relief CompletedThis study tested whether a very low dose of an existing drug, naltrexone, could improve daily life for people with vasculitis, a group of rare autoimmune diseases that cause blood vessel inflammation. Sixty patients whose disease was stable but who still struggled with poor phys…
Matched conditions: GIANT CELL ARTERITIS
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Mar 30, 2026 14:33 UTC
-
First look: testing a new IV treatment for painful inflammatory diseases
Knowledge-focused CompletedThis study aimed to understand how the body processes a drug called secukinumab when given through an IV (intravenous) line, and to check its safety. It involved 65 adults with either giant cell arteritis (GCA) or polymyalgia rheumatica (PMR), two painful inflammatory conditions.…
Matched conditions: GIANT CELL ARTERITIS
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Mar 17, 2026 13:08 UTC